Discussing Post Hoc Analyses from the REACH2 Trial : Episode 5

Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial

April 14, 2023

By Nelson J. Chao, MD, MBA
Michael Grunwald, MD

Video

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD draw conclusions from two post hoc analyses of the REACH2 trial and share clinical pearls for community clinicians treating patients with acute Graft-Versus-Host Disease.

EP: 1.Understanding Acute Graft-Versus-Host Disease

EP: 2.Standard Treatments for Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

EP: 3.REACH 2 Post Hoc Analysis Review: and The Impact of Cytopenias on Patient Outcomes

EP: 4.Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib

Now Viewing

Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial

EP: 1.Understanding Acute Graft-Versus-Host Disease

EP: 2.Standard Treatments for Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

EP: 3.REACH 2 Post Hoc Analysis Review: and The Impact of Cytopenias on Patient Outcomes

EP: 4.Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib

EP: 5.Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial

EP: 6.Recap: Post Hoc Analysis Highlights Impact of Cytopenias on Response Rates in Acute GVHD